Skip to main content

Erratum to: Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants

The Original Article was published on 19 August 2015

After publication of this article, it has come to our attention that a few corrections had not been updated. We are publishing this erratum to highlight what has been updated from the original article. The updates are as follows:-

Abstract – the abstract has been updated to reflect the figures in Table 2, patient survival percentage has been updated from 52.5 % to 52.8 %.

Table 2 – The P value for Freedom from acute rejection, graft failure or death has been updated from 0.05 to 0.04.

Figure 3 captions were incorrect on the original article. This has now been updated. The caption for 3b was updated from Patient survival to Death-censored graft survival. The caption for 3c was updated from Death censored graft survival to Patient Survival.

The corresponding text relating to Fig. 3 has also been updated in line with the figure changes. In the original article it was:-

Patient survival was numerically and statistically similar in both treatment groups at 5 years and equivalent at 10 years (rATG, 52.8 %; basiliximab, 52.2 %; P = 0.92) (Fig. 3b). Death-censored graft survival was also equivalent in the two groups by 10 years (rATG, 68.5 %; basiliximab, 68.4 %; two-sided P = 0.80) (Fig. 3c). Combining trends in mortality and graft failure, all-cause graft survival was generally similar over time among participants randomized to both trial arms, and by 10 years was 34.3 % in those treated with rATG versus 30.9 % in those treated with basiliximab at (two-sided P = 0.56) (Fig. 3d).

This has now been updated to the following:-

Death-censored graft survival was also equivalent in the two groups by 10 years (rATG, 68.5 %; basiliximab, 68.4 %; two-sided P = 0.80) (Fig. 3b). Patient survival was numerically and statistically similar in both treatment groups at 5 years and equivalent at 10 years (rATG, 52.8 %; basiliximab, 52.2 %; P = 0.92) (Fig. 3c). Combining trends in mortality and graft failure, all-cause graft survival was generally similar over time among participants randomized to both trial arms, and by 10 years was 34.3 % in those treated with rATG versus 30.9 % in those treated with basiliximab (two-sided P = 0.56) (Fig. 3d).

Reference

  1. Lentine KL, Schnitzler MA, Xiao H, Brennan DC. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants. Trials. 2015;16:635.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Krista L. Lentine.

Additional information

The online version of the original article can be found under doi:10.1186/s13063-015-0891-y.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lentine, K.L., Schnitzler, M.A., Xiao, H. et al. Erratum to: Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants. Trials 16, 412 (2015). https://doi.org/10.1186/s13063-015-0940-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13063-015-0940-6